Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare

被引:6
|
作者
Kan, Kaying [1 ]
Lokkerbol, Joran [2 ]
Jorg, Frederike [1 ,3 ]
Visser, Ellen [4 ]
Schoevers, Robert A. [5 ]
Feenstra, Talitha L. [6 ,7 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Psychiat, Rob Giel Res Ctr,Interdisciplinary Ctr Psychopath, POB 30001,Hosp Zip Code CC72, NL-9700 RB Groningen, Netherlands
[2] Netherlands Inst Mental Hlth & Addic, Ctr Econ Evaluat & Machine Learning, Trimbos Inst, Utrecht, Netherlands
[3] GGZ Friesland, Res Dept, Leeuwarden, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Psychiat, Rob Giel Res Ctr, Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Univ Ctr Psychiat, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands
[6] Univ Groningen, Groningen Res Inst Pharm, Dept Sci & Engn, Groningen, Netherlands
[7] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
关键词
PERSONALITY-DISORDER; SYSTEMATIC ANALYSIS; ECONOMIC BURDEN; GLOBAL BURDEN; PREVALENCE; DISABILITY; ILLNESS; POPULATION; RECURRENCE; RECOVERY;
D O I
10.1007/s40273-021-01012-x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background The majority of patients with major depressive disorder (MDD) have comorbid mental conditions. Objectives Since most cost-of-illness studies correct for comorbidity, this study focuses on mental healthcare utilization and treatment costs in patients with MDD including psychiatric comorbidities in specialist mental healthcare, particularly patients with a comorbid personality disorder (PD). Methods The Psychiatric Case Register North Netherlands contains administrative data of specialist mental healthcare providers. Treatment episodes were identified from uninterrupted healthcare use. Costs were calculated by multiplying care utilization with unit prices (price level year: 2018). Using generalized linear models, cost drivers were investigated for the entire cohort. Results A total of 34,713 patients had MDD as a primary diagnosis over the period 2000-2012. The number of patients with psychiatric comorbidities was 24,888 (71.7%), including 13,798 with PD. Costs were highly skewed, with an average +/- standard deviation cost per treatment episode of euro21,186 +/- 74,192 (median euro2320). Major cost drivers were inpatient days and daycare days (50 and 28% of total costs), occurring in 12.7 and 12.5% of episodes, respectively. Compared with patients with MDD only (euro11,612), costs of patients with additional PD and with or without other comorbidities were, respectively, 2.71 (p < .001) and 2.06 (p < .001) times higher and were 1.36 (p < .001) times higher in patients with MDD and comorbidities other than PD. Other cost drivers were age, calendar year, and first episodes. Conclusions Psychiatric comorbidities (especially PD) in addition to age and first episodes drive costs in patients with MDD. Knowledge of cost drivers may help in the development of future stratified disease management programs.
引用
收藏
页码:721 / 730
页数:10
相关论文
共 50 条
  • [1] Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare
    Kaying Kan
    Joran Lokkerbol
    Frederike Jörg
    Ellen Visser
    Robert A. Schoevers
    Talitha L. Feenstra
    [J]. PharmacoEconomics, 2021, 39 : 721 - 730
  • [2] Psychiatric comorbidities in patients with major depressive disorder
    Thaipisuttikul, Papan
    Ittasakul, Pichai
    Waleeprakhon, Punjaporn
    Wisajun, Pattarabhorn
    Jullagate, Sudawan
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 2097 - 2103
  • [3] Psychiatric comorbidities in patients with major depressive disorder
    Thaipisuttikul, P.
    Ittasakul, P.
    Waleeprakhon, P.
    Wisajun, P.
    Jullagate, S.
    [J]. ASIA-PACIFIC PSYCHIATRY, 2015, 7 : 11 - 11
  • [4] IMPACT OF BIPOLAR DISORDER TREATMENT DISCONTINUATION ON HEALTHCARE UTILIZATION AND COSTS IN THE REAL-WORLD SETTING
    Khandker, R.
    Chekani, F.
    Limone, B.
    Thiel, E.
    [J]. VALUE IN HEALTH, 2021, 24 : S137 - S137
  • [5] Real-world treatment modalities, health care resource utilization, and costs among commercially insured patients with newly diagnosed major depressive disorder in the United States
    Pizzicato, Lia N.
    Xie, Richard Z.
    Yang, Yiling
    Grabner, Michael
    Chapman, Richard H.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (06): : 614 - 625
  • [6] Mental Health Treatment Dose and Annual Healthcare Costs in Patients With Cancer and Major Depressive Disorder
    Mausbach, Brent T.
    Bos, Taylor
    Irwin, Scott A.
    [J]. HEALTH PSYCHOLOGY, 2018, 37 (11) : 1035 - 1040
  • [7] Treatment Costs in Secondary and Tertiary Mental Health Care in Patients with Major Depressive Disorder
    Kan, Kaying
    Lokkerbol, Joran
    Jorg, Frederike
    Visser, Ellen
    Schoevers, Robert
    Feenstra, Talitha
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2017, 20 : S18 - S18
  • [8] CHARACTERISTICS AND HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH MAJOR DEPRESSIVE DISORDER CONTINUING, SWITCHING, OR DISCONTINUING THERAPY IN A REAL-WORLD SETTING
    Lawrence, D.
    Touya, M.
    Wu, S. J.
    Teng, C. C.
    Wang, L.
    Chrones, L.
    Patel, S.
    Clayton, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S204 - S204
  • [9] Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium
    Gillain, B.
    Degraeve, G.
    Dreesen, T.
    De Bruecker, G.
    Buntinx, E.
    Beke, D.
    Kestens, C.
    Valassopoulou, E.
    Verhelst, F.
    Peeters, E.
    Pype, S.
    De Vos, C.
    Strens, D.
    Vandersmissen, I
    [J]. PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 293 - 302
  • [10] Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium
    B. Gillain
    G. Degraeve
    T. Dreesen
    G. De Bruecker
    E. Buntinx
    D. Beke
    C. Kestens
    E. Valassopoulou
    F. Verhelst
    E. Peeters
    S. Pype
    C. De Vos
    D. Strens
    I. Vandersmissen
    [J]. PharmacoEconomics - Open, 2022, 6 : 293 - 302